Trials / Completed
CompletedNCT01088672
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Stryker Neurovascular · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients. * Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure.
Detailed description
* Clinical outcomes at 90 days * Mortality at 90 days * Device-related serious adverse events (DRSAEs) * Symptomatic ICH rate within 24 (-6/+12) hours post-procedure
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Mechanical Thrombectomy | The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke. |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2011-08-01
- Completion
- 2011-11-01
- First posted
- 2010-03-17
- Last updated
- 2015-07-17
- Results posted
- 2015-07-17
Locations
7 sites across 4 countries: Austria, Germany, Spain, Sweden
Source: ClinicalTrials.gov record NCT01088672. Inclusion in this directory is not an endorsement.